June 20, 2026 — RNews

#antibody — Saturday, June 20, 2026 (1 items)

hot top new

← prev day next day →

0

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial. (linkinghub.elsevier.com)

Lenz G … Vitolo U The Lancet 2026-06-20

#antibody #clinical trial #immunotherapy #chemotherapy #lymphoma